Zura Bio (ZURA) Competitors

$4.36 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.44 +0.08 (+1.81%)

As of 05/22/2026 06:23 PM Eastern

ZURA vs. RXRX, GHRS, ARDX, TSHA, and GLUE

Should you buy Zura Bio stock or one of its competitors? MarketBeat compares Zura Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zura Bio include Recursion Pharmaceuticals (RXRX), GH Research (GHRS), Ardelyx (ARDX), Taysha Gene Therapies (TSHA), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

How does Zura Bio compare to Recursion Pharmaceuticals?

Zura Bio (NASDAQ:ZURA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 2 mentions for Zura Bio. Recursion Pharmaceuticals' average media sentiment score of 0.76 beat Zura Bio's score of 0.05 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Zura Bio currently has a consensus price target of $10.75, suggesting a potential upside of 146.56%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 169.10%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Zura Bio has higher earnings, but lower revenue than Recursion Pharmaceuticals. Zura Bio is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Recursion Pharmaceuticals	$74.68M	21.36	-$644.76M	-$1.20	N/A

Zura Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 14.2% of Zura Bio shares are held by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Zura Bio has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Summary

Recursion Pharmaceuticals beats Zura Bio on 9 of the 16 factors compared between the two stocks.

How does Zura Bio compare to GH Research?

GH Research (NASDAQ:GHRS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

56.9% of GH Research shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GH Research presently has a consensus target price of $40.38, suggesting a potential upside of 82.53%. Zura Bio has a consensus target price of $10.75, suggesting a potential upside of 146.56%. Given Zura Bio's higher possible upside, analysts clearly believe Zura Bio is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

GH Research is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

GH Research has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

GH Research's return on equity of -19.36% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Zura Bio	N/A	-55.74%	-48.07%

In the previous week, GH Research had 7 more articles in the media than Zura Bio. MarketBeat recorded 9 mentions for GH Research and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.05 beat GH Research's score of -0.86 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GH Research beats Zura Bio on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Ardelyx?

Zura Bio (NASDAQ:ZURA) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

In the previous week, Ardelyx had 14 more articles in the media than Zura Bio. MarketBeat recorded 16 mentions for Ardelyx and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.05 beat Ardelyx's score of -0.26 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zura Bio presently has a consensus price target of $10.75, suggesting a potential upside of 146.56%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 156.96%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Zura Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Zura Bio. Ardelyx is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Ardelyx	$407.32M	3.71	-$61.60M	-$0.23	N/A

Zura Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Ardelyx	-13.58%	-38.11%	-11.85%

Summary

Ardelyx beats Zura Bio on 10 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Taysha Gene Therapies currently has a consensus target price of $11.64, indicating a potential upside of 111.96%. Zura Bio has a consensus target price of $10.75, indicating a potential upside of 146.56%. Given Zura Bio's higher possible upside, analysts plainly believe Zura Bio is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Zura Bio had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Taysha Gene Therapies. Zura Bio's average media sentiment score of 0.05 beat Taysha Gene Therapies' score of 0.00 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	161.47	-$109M	-$0.38	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Zura Bio's return on equity of -55.74% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Zura Bio	N/A	-55.74%	-48.07%

Taysha Gene Therapies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Zura Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Taysha Gene Therapies beats Zura Bio on 8 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Monte Rosa Therapeutics?

Zura Bio (NASDAQ:ZURA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Monte Rosa Therapeutics has higher revenue and earnings than Zura Bio. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Monte Rosa Therapeutics	$123.67M	12.85	-$38.63M	-$1.48	N/A

Zura Bio has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zura Bio currently has a consensus target price of $10.75, indicating a potential upside of 146.56%. Monte Rosa Therapeutics has a consensus target price of $32.50, indicating a potential upside of 72.78%. Given Zura Bio's higher probable upside, research analysts clearly believe Zura Bio is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Zura Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.05 beat Monte Rosa Therapeutics' score of 0.00 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monte Rosa Therapeutics beats Zura Bio on 8 of the 15 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$413.68M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-4.00	10.34	17.93	22.89
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.90	7.09	10.37	7.14
Net Income	-$99.35M	$24.45M	$3.57B	$335.98M
7 Day Performance	5.83%	5.45%	6.01%	3.56%
1 Month Performance	-18.96%	2.43%	3.52%	2.54%
1 Year Performance	327.45%	62.98%	34.13%	35.05%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.975 of 5 stars	$4.36 flat	$10.75 +146.6%	+327.5%	$413.68M	N/A	N/A	3
RXRX Recursion Pharmaceuticals	3.3855 of 5 stars	$2.85 -1.4%	$8.10 +184.2%	-26.2%	$1.51B	$74.68M	N/A	400	Gap Up
GHRS GH Research	2.9041 of 5 stars	$21.94 +1.2%	$40.38 +84.0%	+98.0%	$1.51B	N/A	N/A	10	Gap Up
ARDX Ardelyx	2.887 of 5 stars	$6.09 -0.3%	$15.70 +157.8%	+53.9%	$1.50B	$407.32M	N/A	90	News Coverage Positive News
TSHA Taysha Gene Therapies	2.5407 of 5 stars	$5.18 -5.0%	$11.64 +124.6%	+99.6%	$1.49B	$9.77M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. RXRX, GHRS, ARDX, TSHA, and GLUE

How does Zura Bio compare to Recursion Pharmaceuticals?

Summary

How does Zura Bio compare to GH Research?

Summary

How does Zura Bio compare to Ardelyx?

Summary

How does Zura Bio compare to Taysha Gene Therapies?

Summary

How does Zura Bio compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. RXRX, GHRS, ARDX, TSHA, and GLUE

How does Zura Bio compare to Recursion Pharmaceuticals?

Does the media favor ZURA or RXRX?

Do analysts recommend ZURA or RXRX?

Which has higher earnings & valuation, ZURA or RXRX?

Which has more risk and volatility, ZURA or RXRX?

Do institutionals & insiders hold more shares of ZURA or RXRX?

Is ZURA or RXRX more profitable?

Summary

How does Zura Bio compare to GH Research?

Do insiders and institutionals hold more shares of GHRS or ZURA?

Do analysts rate GHRS or ZURA?

Which has better earnings and valuation, GHRS or ZURA?

Which has more risk and volatility, GHRS or ZURA?

Is GHRS or ZURA more profitable?

Does the media refer more to GHRS or ZURA?

Summary

How does Zura Bio compare to Ardelyx?

Does the media prefer ZURA or ARDX?

Do insiders & institutionals have more ownership in ZURA or ARDX?

Do analysts recommend ZURA or ARDX?

Which has more volatility and risk, ZURA or ARDX?

Which has stronger valuation and earnings, ZURA or ARDX?

Is ZURA or ARDX more profitable?

Summary

How does Zura Bio compare to Taysha Gene Therapies?

Do analysts prefer TSHA or ZURA?

Does the media refer more to TSHA or ZURA?

Which has better valuation & earnings, TSHA or ZURA?

Is TSHA or ZURA more profitable?

Which has more risk and volatility, TSHA or ZURA?

Do insiders & institutionals believe in TSHA or ZURA?

Summary

How does Zura Bio compare to Monte Rosa Therapeutics?

Which has preferable earnings & valuation, ZURA or GLUE?

Is ZURA or GLUE more profitable?

Do institutionals and insiders have more ownership in ZURA or GLUE?

Do analysts rate ZURA or GLUE?

Which has more volatility & risk, ZURA or GLUE?

Does the media prefer ZURA or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools